Sparsentan

CAS No. 254740-64-2

Sparsentan( RE-021 | DARA-a )

Catalog No. M21831 CAS No. 254740-64-2

Sparsentan (RE-021) is a highly potent dual angiotensin II and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 70 In Stock
5MG 113 In Stock
10MG 165 In Stock
25MG 267 In Stock
50MG 410 In Stock
100MG 602 In Stock
500MG 1278 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Sparsentan
  • Note
    Research use only, not for human use.
  • Brief Description
    Sparsentan (RE-021) is a highly potent dual angiotensin II and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively.
  • Description
    Sparsentan (RE-021) is a highly potent dual angiotensin II and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively.(In Vivo):Sparsentan dose dependently antagonizes the angiotensin II-induced pressor response with an ED50 value of 0.8 μmol/kg iv and 3.6 μmol/kg po. Sparsentan also shows efficacious and long acting in the big ET-1-induced pressor model. Sparsentan causes a significant lowering of blood pressure at the lowest dose tested (10 μmol/kg/day) in spontaneously hypertensive rats. Sparsentan shows good oral bioavailability in rats, dogs, and monkeys, averaging 40%, 86%, and 21% F, respectively. At 100 μmol/kg/day, Sparsentan reduces the blood pressure from 170 to less than 100 mmHg during the course of the drug’s pharmacokinetic duration. Sparsentan at 100 μmol/kg/day essentially converts the spontaneously hypertensive rats into normotensive rats during the course of its pharmacokinetic duration.
  • In Vitro
    ——
  • In Vivo
    Sparsentan dose dependently antagonizes the angiotensin II-induced pressor response with an ED50 value of 0.8 μmol/kg iv and 3.6 μmol/kg po. Sparsentan also shows efficacious and long acting in the big ET-1-induced pressor model. Sparsentan causes a significant lowering of blood pressure at the lowest dose tested (10 μmol/kg/day) in spontaneously hypertensive rats. Sparsentan shows good oral bioavailability in rats, dogs, and monkeys, averaging 40%, 86%, and 21% F, respectively. At 100 μmol/kg/day, Sparsentan reduces the blood pressure from 170 to less than 100 mmHg during the course of the drug’s pharmacokinetic duration. Sparsentan at 100 μmol/kg/day essentially converts the spontaneously hypertensive rats into normotensive rats during the course of its pharmacokinetic duration.
  • Synonyms
    RE-021 | DARA-a
  • Pathway
    GPCR/G Protein
  • Target
    Angiotensin Receptor
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    254740-64-2
  • Formula Weight
    592.75
  • Molecular Formula
    C??H??N?O?S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 250 mg/mL (421.76 mM; Need ultrasonic);H2O : < 0.1 mg/mL (insoluble)
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Murugesan N, et al. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. J Med Chem. 2005 Jan 13;48(1):171-9.
molnova catalog
related products
  • EMA401

    EMA401 (Olodanrigan) is a potent, highly selective angiotensin II type 2 receptor (AT2R) antagonist, inhibits capsaicin responses in cultured neurons of human and rat DRG with IC50 of 10 nM.

  • Azilsartan medoxomil

    A specific and potent angiotensin II type 1 receptor (AT1) antagonist with IC50 of 2.6 nM.

  • Angiotensin 1-7

    Angiotensin (1-7) (Ang-(1-7)) is an active heptapeptide of the Renin-angiotensin system (RAS).